Advance of Research on the Immunotherapy Targeting B Cell Maration Antigen for Multiple Myeloma--Review / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 1701-1705, 2019.
Article
en Zh
| WPRIM
| ID: wpr-775662
Biblioteca responsable:
WPRO
ABSTRACT
Abstract B cell maturation antigen (BCMA) is an ideal target for precise treatment due to its highly selective expression on malignant myeloma cells. This review summarizes briefly the advances in the latest research progress on biological activity of BCMA, its significance as a biomarker and immunotherapy direcited against BCMA, such as bispecific antibodies, antibody drug conjugates, chimeric antigen receptor T cell therapy against mature B cell antigens.
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Terapéutica
/
Linfocitos B
/
Linfocitos T
/
Antígenos de Diferenciación de Linfocitos B
/
Antígeno de Maduración de Linfocitos B
/
Inmunoterapia
/
Mieloma Múltiple
Límite:
Humans
Idioma:
Zh
Revista:
Journal of Experimental Hematology
Año:
2019
Tipo del documento:
Article